FY2024 EPS Estimates for OmniAb Increased by Leerink Partnrs

OmniAb, Inc. (NASDAQ:OABI) – Leerink Partnrs lifted their FY2024 earnings estimates for OmniAb in a research report issued to clients and investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now expects that the company will earn ($0.59) per share for the year, up from their previous forecast of ($0.62). The consensus estimate for OmniAb’s current full-year earnings is ($0.62) per share.

OABI has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of OmniAb in a research report on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and set a $8.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Stock Performance

OABI stock opened at $3.57 on Thursday. The stock’s fifty day moving average is $3.90 and its two-hundred day moving average is $4.10. OmniAb has a 1 year low of $3.43 and a 1 year high of $6.72. The stock has a market capitalization of $504.14 million, a price-to-earnings ratio of -5.76 and a beta of -0.10.

Institutional Investors Weigh In On OmniAb

A number of institutional investors have recently bought and sold shares of the business. Atria Investments Inc purchased a new position in OmniAb in the third quarter valued at about $148,000. FMR LLC grew its position in OmniAb by 10.6% in the third quarter. FMR LLC now owns 138,813 shares of the company’s stock worth $587,000 after acquiring an additional 13,324 shares in the last quarter. Murchinson Ltd. bought a new position in shares of OmniAb in the third quarter valued at approximately $4,230,000. Barclays PLC boosted its holdings in shares of OmniAb by 321.5% during the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock worth $606,000 after buying an additional 109,236 shares during the period. Finally, State Street Corp grew its stake in OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock valued at $8,594,000 after buying an additional 34,654 shares during the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.